

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Previously presented) An isolated antibody comprising  
a V<sub>H</sub> domain having a CDR1 comprising the sequence set forth in SEQ ID NO:6,  
a CDR2 comprising the sequence set forth in SEQ ID NO:7, and a CDR3 comprising the  
sequence set forth in SEQ ID NO:8; and  
a V<sub>L</sub> domain having a CDR1 comprising the sequence set forth in SEQ ID NO:3,  
a CDR2 comprising the sequence set forth in SEQ ID NO:4, and a CDR3 comprising the  
sequence set forth in SEQ ID NO:5,  
wherein the antibody can bind to Factor IX/Factor IXa and increase the  
procoagulation activity of Factor IXa.
- 2-7. (Canceled)
8. (Previously presented) The isolated antibody according to claim 1, wherein the V<sub>H</sub> domain comprises the sequence set forth in SEQ ID NO: 1 and  
the V<sub>L</sub> domain comprises the sequence set forth in SEQ ID NO:2.
9. (Previously presented) The isolated antibody according to claim 1, wherein the antibody is an IgG.
10. (Previously presented) The isolated antibody according to claim 1, wherein the antibody is a monoclonal.
11. (Previously presented) The isolated antibody according to claim 1, wherein the antibody is an antibody fragment.

12. (Previously presented) The isolated antibody according to claim 1, wherein the antibody is a recombinant antibody.

13. (Previously presented) The isolated antibody according to claim 12, wherein the antibody is a single chain antibody.

14. (Previously presented) The isolated antibody according to claim 1, wherein the antibody is a humanized antibody.

15. (Previously presented) The isolated antibody of claim 1, wherein the antibody is labeled.

16-21. (Canceled)

22. (Currently amended) A pharmaceutical composition comprising ~~an~~ the isolated antibody of claim 1 and a pharmaceutically acceptable carrier and/or diluent.

23. (Previously presented) The pharmaceutical composition comprising the isolated antibody of claim 8.

24. (Previously presented) The pharmaceutical composition according to claim 23, further comprising a Factor selected from the group consisting of Factor IX, Factor IX $\alpha$ , Factor IX $\alpha$  $\beta$ , and combinations thereof.

25-27. (Canceled)

28. (Previously presented) The pharmaceutical composition according to claim 22, further comprising a Factor selected from the group consisting of Factor IX, Factor IX $\alpha$ , Factor IX $\alpha$  $\beta$ , and combinations thereof.